Vaxart Inc (VXRT)

$4.29 0. (0.00%)

16:00 EDT VXRT Stock Quote Delayed 30 Minutes

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

By William White, InvestorPlace Writer May 10, 2022

Good morning! We're starting off another busy day of trading with a breakdown of the biggest pre-market stock movers for Tuesday!

3 Stocks That Have Analysts Running for the Exit

Vaxart: Oral Covid-19 Vaccine Is Interesting, But Questions Linger

Vaxart Deserves More Respect on Wall Street for Its Promising Covid-19 Vaccine

Volume:

Previous Close -

Market Cap 542.71M

PE Ratio -9.75

EPS -0.44

Volume (Avg. Vol.) 300

Day's Range -

52-Week Range $2.49 - $10.33

Dividend & Yield N/A (N/A)

VXRT Stock Predictions, Articles, and Vaxart Inc News

From InvestorPlace
From the Web

VXRT Stock: Other Vaccine Stocks Are Gaining But Jim Cramer Just Sent Vaxart Down

By Shrey Dua, InvestorPlace Assistant News Writer Dec 1, 2021

Despite a new factory acquisition, VXRT stock is down 9% on the day as 'Mad Money' host Jim Cramer warns investors about Vaxart.

Don’t Write Off Vaxart, As Its Oral Vaccine Still Has a Chance

By Louis Navellier and the InvestorPlace Research Staff Oct 20, 2021

VXRT stock is still worth a shot, as there's still big potential demand for a "no-needle" Covid-19 vaccine alternative.

Why Investing in VXRT Stock is a Coin Flip

By Chris Lau, InvestorPlace Contributor Oct 6, 2021

Vaxart is a gamble for biotechnology investors, with its upside too dependent on the approval of an oral vaccine.

Vaccine Stocks: Why MRNA, VXRT, CVAC and NVAX Stocks Need a Band-Aid Today

By Chris MacDonald, InvestorPlace Contributor Oct 1, 2021

Today, vaccine stocks are taking a massive hit as investors price in the potential effect of oral medications for Covid-19 on this sector.

Vaxart Traders Should Not Dismiss the Vaccine Maker’s Momentum

By Louis Navellier and the InvestorPlace Research Staff Sep 27, 2021

The recently range-bound price action of VXRT stock doesn't reflect the progress that Vaxart is making against Covid-19.

It’s Time to Start Thinking Seriously About Vaxart

By Josh Enomoto, InvestorPlace Contributor Sep 22, 2021

While VXRT stock is risky due to underlying clinical challenges, the evolving nature of Covid-19 makes it worth consideration.

Vaxart Stock Is One Vaccine Also-Ran Worth Another Look

By Thomas Niel Sep 8, 2021

If you're looking to wager on a vaccine long-shot, place your bet on VXRT stock.

Is Vaxart Stock Really Worth a Shot?

By Louis Navellier and the InvestorPlace Research Staff Aug 30, 2021

VXRT stock still has hope as Vaxart is developing modern rDNA vaccines in pill form (including a Covid-19 vaccine), aiming to overcome needle challenges.

Longshot Covid Play Vaxart Stock Is Too Risky at These Prices

By Will Ashworth, InvestorPlace Contributor Aug 27, 2021

Vaxart got approval Aug. 2 for a Phase II trial for its oral Covid-19 vaccine. VXRT stock has gained 22% since. Should you buy on momentum?

Vaxart Is Another Risky Biotech Stock to Avoid Right Now

By Stavros Georgiadis, CFA, InvestorPlace Contributor Aug 17, 2021

VRXT stock is highly overvalued. Investors are holding out for its Covid-19 vaccine, but it may not be approved in time to boost shares.

7 Biotech Stocks to Buy Amid the Delta Variant’s Onslaught

By Josh Enomoto, InvestorPlace Contributor Aug 11, 2021

You may have thought the moment of relevancy for these biotech stocks was over, but the Delta variant has changed their prospects.

The Delta Variant Is a Shot in the Arm for Vaxart’s Pill Vaccine

By Mark R. Hake, CFA Aug 10, 2021

The Delta Covid variant gives Vaxart new life with its oral vaccine and could boost VRXT stock. VXRT stock is worth over 30% more at $13.00 if its Covid pill works, according to sell-side analysts.